The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Open accessAbstract
Purpose: To update the ASCO clinical practice guideline on adjuvant endocrine therapy on the basis of emerging data on the optimal duration of treatment, particularly adjuvant tamoxifen. Methods: ASCO convened the Update Committee and conducted a systematic review of randomized clinical trials from January 2009 to June 2013 and analyzed three historical trials. Guideline recommendations were based on the Update Committee's review of the evidence. Outcomes of interest included survival, disease recurrence, and adverse events. Results: This guideline update reflects emerging data on duration of tamoxifen treatment. There have been five studies of tamoxifen treatment beyond 5 years of therapy. The two largest studies with longest reported follow-up show a breast cancer survival advantage with 10-year durations of tamoxifen use. In addition to modest gains in survival, extended therapy with tamoxifen for 10 years compared with 5 years was associated with lower risks of breast cancer recurrence and contralateral breast cancer. Recommendations: Previous ASCO guidelines recommended treatment of women who have hormone receptor–positive breast cancer and are premenopausal with 5 years of tamoxifen, and those who are postmenopausal a minimum of 5 years of adjuvant therapy with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor (in sequence). If women are pre- or perimenopausal and have received 5 years of adjuvant tamoxifen, they should be offered 10 years total duration of tamoxifen. If women are postmenopausal and have received 5 years of adjuvant tamoxifen, they should be offered the choice of continuing tamoxifen or switching to an aromatase inhibitor for 10 years total adjuvant endocrine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Self-citationWiner, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Self-citationAdherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients
Naderi, S. H., Bestwick, J. P., & Wald, D. S. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.12.013 · Cited by 846
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3756 · Cited by 796
Self-citationMurphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708 · cited 3×
“Clinicians imparting knowledge about recurrence may also increase persistence,(24) as may the provision of follow-up care in the oncology setting.(24)”
BackgroundInfluentialFisher, B., Dignam, J., Bryant, J., & Wolmark, N. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.684 · Cited by 635
Khatcheressian, J. L., Hurley, P., Bantug, E., Esserman, L. J., Grunfeld, E., Halberg, F., Hantel, A., Henry, N. L., Muss, H. B., Smith, T. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9859 · Cited by 626
Self-citationHammond, M. E. H., Hayes, D. F., Wolff, A. C., Mangu, P. B., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.777003 · Cited by 583
Self-citationGray, R. G., Rea, D., Handley, K., Bowden, S. J., Perry, P., Earl, H. M., Poole, C. J., Bates, T., Chetiyawardana, S., Dewar, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.18_suppl.5 · Cited by 451
Mamounas, E. P., Jeong, J.-H., Wickerham, D. L., Smith, R. E., Ganz, P. A., Land, S. R., Eisen, A., Fehrenbacher, L., Farrar, W. B., Atkins, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0228 · Cited by 341
American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04187.x · Cited by 308
(2008) · Cited by 225
Tormey, D. C., Gray, R., Falkson, H. C., & For the Eastern Cooperative Oncology Group (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.24.1828 · Cited by 201
Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.020 · Cited by 200
Self-citationScottish Adjuvant Tamoxifen Trial: a Randomized Study Updated to 15 Years
Stewart, H. J., Prescott, R. J., & Forrest, A. P. M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.6.456 · Cited by 197
Wu, X.-C., Lund, M. J., Kimmick, G. G., Richardson, L. C., Sabatino, S. A., Chen, V. W., Fleming, S. T., Morris, C. R., Huang, B., Trentham-Dietz, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8399 · Cited by 190
Shiffman, R. N., Michel, G., Rosenfeld, R. M., & Davidson, C. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000172 · Cited by 184
The Scottish Cancer Trials Breast Group, Stewart, H., Forrest, A., Everington, D., McDonald, C., Dewar, J., Hawkins, R., Prescott, R., & George, W. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.356 · Cited by 177
Sherrill, B., Halpern, M., Khan, S., Zhang, J., & Panjabi, S. (2011) · The Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00550.x · Cited by 160
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M. M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4482 · Cited by 140
Self-citationBowles, E. J. A., Boudreau, D. M., Chubak, J., Yu, O., Fujii, M., Chestnut, J., & Buist, D. S. M. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2012.000543 · Cited by 133
Muszbek, N., Brixner, D. I., Benedict, Á., Keskinaslan, A., & Khan, Z. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01683.x · Cited by 110
Racial and Ethnic Disparities in Care: The Perspectives of Cardiologists
Lurie, N., Fremont, A., Jain, A. K., Taylor, S. L., McLaughlin, R., Peterson, E., Kong, B. W., & Ferguson, T. B. (2005) · Circulation · doi:10.1161/01.cir.0000157738.12783.71 · Cited by 109
Friese, C. R., Pini, T. M., Li, Y., Abrahamse, P. H., Graff, J. J., Hamilton, A. S., Jagsi, R., Janz, N. K., Hawley, S. T., Katz, S. J., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2499-9 · Cited by 95
Self-citationStatin Discontinuation in High-Risk Patients: A Systematic Review of the Evidence
Sandoval, Y.-H. G., Braganza, M. V., & Daskalopoulou, S. S. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798220891 · Cited by 85
Winer, E. P., Hudis, C. A., Burstein, H. J., Bryant, J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gelber, R. D., Gralow, J. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.596 · Cited by 83
Self-citationEffect of Statin Adherence on Cerebrovascular Disease in Primary Prevention
Perreault, S., Ellia, L., Dragomir, A., Côté, R., Blais, L., Bérard, A., & Lalonde, L. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.01.032 · Cited by 67
Letrozole in the extended adjuvant setting: MA.17
Goss, P. E. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9698-1 · Cited by 67
Ingle, J. N., Tu, D., Pater, J. L., Muss, H. B., Martino, S., Robert, N. J., Piccart, M. J., Castiglione, M., Shepherd, L. E., Pritchard, K. I., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm566 · Cited by 67
Self-citationSocioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors
Yen, T. W. F., Czypinski, L. K., Sparapani, R., Guo, C., Laud, P. W., Pezzin, L. E., & Nattinger, A. B. (2010) · Cancer · doi:10.1002/cncr.25412 · Cited by 24
Role of Nonclinical Factors in the Receipt of High-Quality Systemic Adjuvant Breast Cancer Treatment
Griggs, J. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4270 · Cited by 8
Self-citation
Cited by
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Self-citationBurstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Solky, A. J., Stearns, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01160 · Cited by 636
Self-citationOverview of Breast Cancer Therapy
Moo, T.-A., Sanford, R., Dang, C., & Morrow, M. (2018) · PET Clinics · doi:10.1016/j.cpet.2018.02.006 · Cited by 551
Wefel, J. S., Kesler, S. R., Noll, K. R., & Schagen, S. B. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21258 · Cited by 532
Metadata
- Authors
- Burstein, H. J., Temin, S., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Rowden, D., Solky, A. J., Stearns, V., Winer, E. P., & Griggs, J. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-07-20
- Volume
- 32
- Issue
- 21
- Pages
- 2255-2269
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131199058
- Cited by
- 786
- References
- 34
- FWCI
- 32.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.